We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO to Present at the 20th Annual Future Leaders in the Biotech Industry Conference
WALTHAM, Mass., March 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 20 th Annual Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel and Conference
View HTML
Toggle Summary TESARO Announces Closing of Public Offering and Full Exercise of Over-Allotment Option by Underwriters
WALTHAM, Mass., March 5, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today the closing of its previously announced underwritten public offering of common stock. The total number of shares of common stock sold was 5,428,000, composed of 4,720,000 shares of common stock initially
View HTML
Toggle Summary TESARO Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 4,720,000 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds from the offering will be
View HTML
Toggle Summary TESARO Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional
View HTML
Toggle Summary TESARO Announces Fourth Quarter and Year-End 2012 Operating Results
Niraparib to be Advanced in a Phase 3 Pivotal Trial for Ovarian Cancer Enrollment Continues in the Global Registration Program for Rolapitant Achieved Third Dose-level in a Phase 1/2 Clinical Trial of TSR-011 WALTHAM, Mass., Feb. 14, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML
Toggle Summary TESARO to Announce Fourth Quarter and Year End 2012 Financial Results on Thursday, February 14th, 2013
WALTHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter and year end 2012 financial results on Thursday, February 14 th , 2013, before the opening of the U.S. financial markets. TESARO's senior management will host a conference call and live
View HTML
Toggle Summary TESARO to Present at the Leerink Swann Global Healthcare Conference
WALTHAM, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Leerink Swann Global Healthcare Conference at the Waldorf Astoria Hotel
View HTML
Toggle Summary TESARO to Present at the Deutsche Bank 2012 dbAccess BioFEST
WALTHAM, Mass., Nov. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Deutsche Bank 2012 dbAccess BioFEST at the Four Seasons Hotel in
View HTML
Toggle Summary TESARO and Virginia G. Piper Cancer Center Announce Enrollment of First Patient in Clinical Trial of TSR-011
Company Plans to Expand Phase 1/2 Clinical Trial of the Anaplastic Lymphoma Kinase (ALK) Inhibitor, TSR-011, to Multiple Clinical Trial Sites
View HTML
Toggle Summary TESARO Announces Third Quarter 2012 Operating Results
Continued Enrollment for the Global Registration Program for Rolapitant Announced Clearance of Investigational New Drug Application for TSR-011 Appointed Robert E. Martell, M.D., Ph.D., as Chief Medical Officer WALTHAM, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc.
View HTML